SEC Tracker
Get the app

Coherus Oncology CHRS

Coherus Oncology (CHRS) filed an 8-K report on November 13, 2025, announcing the resignation of its CEO, effective immediately. This unexpected leadership change could create uncertainty and impact the company's strategic direction and execution, which investors should closely monitor.

Form
8-K
Filed
Importance
Major

Open in the appGet the appView on EDGAR

Get an email when Coherus Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Entera Bio ENTX public float $85M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025